{"filing":{"accession_number":"0001759138-26-000030","cik":"0001759138","ticker":"CABA","company_name":"Cabaletta Bio, Inc.","form":"8-K","filing_date":"2026-06-03","report_date":null,"primary_document":"caba-20260603.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1759138/000175913826000030/caba-20260603.htm"},"events":[{"id":7325,"run_id":6432,"accession_number":"0001759138-26-000030","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.74,"summary":"Cabaletta Bio disclosed clinical trial data and development updates for rese-cel across its autoimmune portfolio, including encouraging early preconditioning-free lupus findings and anticipated regulatory milestones (SSc registrational program initiation in 4Q26, DM/ASyS topline data in mid-2027, BLA submission in 2H27). For a clinical-stage biotech company, positive clinical trial results and development progress are material to investor assessment of pipeline value and regulatory prospects.","company_name":"Cabaletta Bio, Inc.","ticker":"CABA","filing_date":"2026-06-03","form":"8-K","submitted_at":null,"items":[{"id":4167,"accession_number":"0001759138-26-000030","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"Cabaletta Bio disclosed new rese-cel clinical data and development updates across its autoimmune portfolio, including \"encouraging early preconditioning-free lupus findings.\" For a clinical-stage biotech company, positive clinical trial results and development progress are material to investor assessment of pipeline value and regulatory prospects. However, the disclosure is furnished under Item 7.01 (Regulation FD) rather than a dedicated Item, and the language \"early\" findings suggests preliminary data rather than definitive trial results, which creates some ambiguity about materiality and event classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-04T02:52:06.314900+00:00","company_name":"","ticker":null,"filing_date":""},{"id":4168,"accession_number":"0001759138-26-000030","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"This disclosure announces clinical trial data and development updates for rese-cel across multiple autoimmune indications (myositis, lupus, systemic sclerosis), including encouraging preconditioning-free lupus findings and anticipated regulatory milestones (SSc registrational program initiation in 4Q26, DM/ASyS topline data in mid-2027, BLA submission in 2H27). While the data presentation and development roadmap are material to investors assessing the company's pipeline progress and regulatory trajectory, the disclosure does not fit neatly into the more specific event categories (it is not an earnings release, M\u0026A activity, restatement, impairment, or litigation), making \"other_material\" the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-04T02:52:06.314900+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":4167,"accession_number":"0001759138-26-000030","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"Cabaletta Bio disclosed new rese-cel clinical data and development updates across its autoimmune portfolio, including \"encouraging early preconditioning-free lupus findings.\" For a clinical-stage biotech company, positive clinical trial results and development progress are material to investor assessment of pipeline value and regulatory prospects. However, the disclosure is furnished under Item 7.01 (Regulation FD) rather than a dedicated Item, and the language \"early\" findings suggests preliminary data rather than definitive trial results, which creates some ambiguity about materiality and event classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-04T02:52:06.314900+00:00","company_name":"Cabaletta Bio, Inc.","ticker":"CABA","filing_date":"2026-06-03"},{"id":4168,"accession_number":"0001759138-26-000030","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"This disclosure announces clinical trial data and development updates for rese-cel across multiple autoimmune indications (myositis, lupus, systemic sclerosis), including encouraging preconditioning-free lupus findings and anticipated regulatory milestones (SSc registrational program initiation in 4Q26, DM/ASyS topline data in mid-2027, BLA submission in 2H27). While the data presentation and development roadmap are material to investors assessing the company's pipeline progress and regulatory trajectory, the disclosure does not fit neatly into the more specific event categories (it is not an earnings release, M\u0026A activity, restatement, impairment, or litigation), making \"other_material\" the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-04T02:52:06.314900+00:00","company_name":"Cabaletta Bio, Inc.","ticker":"CABA","filing_date":"2026-06-03"}]}